

Express Mail Label No.: EL831676464US

Date of Deposit: October 15, 2001

Attorney Docket No. 15966-552 CON-S8 (Cura-52 CON-S8)

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

FIRST-NAMED INVENTOR: Shimkets

FOR: NOVEL NUCLEIC ACID SEQUENCES ENCODING HUMAN BREAST  
TUMOR-ASSOCIATED PROTEIN 47-LIKE POLYPEPTIDES

Assistant Commissioner for Patents  
Washington, D.C. 20231


**INFORMATION DISCLOSURE STATEMENT AND ACCOMPANYING  
FORM PTO-1449**

Applicants submit herewith copies of modified PTO-1449 forms submitted in parent application USSN 09/584,411, from which the presently filed application claims priority. Copies of the references listed therein are not enclosed but will be provided upon request. Applicants request that each of the listed documents be made of record in the presently filed application.

This information disclosure statement is being submitted concurrently with the filing of the application. Accordingly, no fee is believed due. However, the Commissioner is authorized to charge any fees due, or credit overpayments of same, to Deposit Account No. 50-0311, Ref. No. 15966-552 CON-S8 (Cura-52 CON-S8).

Respectfully submitted,

Dated: October 15, 2001

  
Ivor R. Elrifi, Reg. No. 39,529  
Naomi S. Biswas, Reg. No. 38,384  
Attorneys for Applicants  
MINTZ, LEVIN, COHN, FERRIS,  
GLOVSKY AND POPEO, P.C.  
One Financial Center  
Boston, Massachusetts 02111  
Tel: (617) 542-6000  
Fax: (617) 542-2241



Please type a plus sign (+) in this box

+

PTO/SB (12-97)

Approved for use through 9/30/00, OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Modified Form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)	<b>Application Number</b>	09/584,411
	<b>Filing Date</b>	5/31/00
	<b>First Named Inventor</b>	Shimkets
	<b>Group Art Unit</b>	1641
	<b>Examiner Name</b>	
	<b>Attorney Docket Number</b>	15966-552

 10/15/01  
 09/27/01  
 U.S. PTO

U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
	A1	5916753	6/29/99	Ni, et al.			
	A2	5942400	8/24/99	Anderson, et al.			

FOREIGN PATENT DOCUMENTS							
Exam Initials	Cite No.	Foreign Patent Document Office	Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes	No
	B1	WO	98/36068-A2	Goli, et al.	8/20/98		
	B2	WO	98/07754-A1	Ni, et al.	2/26/98		
	B3	WO	99/46281-A2	Wood, et al.	9/16/99		
	B4	WO	99/31236-A2	Bougueleret, et al.	6/24/99		
	B5	WO	99/02456-A1	Leary, et al.	1/21/99		
	B6	DE	19813835-A1	Specht et al.	9/23/99		
	B7	WO	99/25825-A2	Bougueleret, et al.	5/27/99		
	B8	WO	99/32626-A1	Sims, J.E.	7/1/99		
	B9	WO	99/57132-A1	Jacobs, et al.	11/11/99		
	B10	WO	99/14328-A2	Wood, et al.	3/25/99		
	B11	WO	99/46380-A2	Tang, et al.	9/16/99		

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	C1	Cannella, B., et al. (1998). "The neuregulin, glial growth factor 2, diminishes autoimmune demyelination and enhances remyelination in a chronic relapsing model for multiple sclerosis." <u>Proc Natl Acad Sci U S A</u> 95(17): 10100-5.
	C2	Gayle, M. A., et al. (1996). "Cloning of a putative ligand for the T1/ST2 receptor." <u>J Biol Chem</u> 271(10): 5784-9.
	C3	<u>GenBank Accession Number ACC:CAA44652 (1991)</u>
	C4	<u>GenBank Accession Number ACC:CAA27525 (1986)</u>
	C5	<u>GenBank Accession Number ACC:BAA11680 (1996)</u>
	C6	<u>GenBank Accession Number ACC:BAA34488 (1998)</u>

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	C7	<i>GenBank Accession Number ACC:L08825 (1993)</i>
	C8	<i>GenBank Accession Number ACC:CAA31302 (1988)</i>
	C9	<i>GenBank Accession Number ACC:A00281 (1989)</i>
	C10	<i>GenBank Accession Number ACC:CAA33109 (1989)</i>
	C11	<i>GenBank Accession Number ACC:CAA30372 (1988)</i>
	C12	<i>GenBank Accession Number ACC:CAA36809 (1990)</i>
	C13	<i>GenBank Accession Number ACC:P05307 (1987)</i>
	C14	<i>GenBank Accession Number ACC:P07237 (1987)</i>
	C15	<i>GenBank Accession Number ACC:P24347 (1990)</i>
	C16	<i>GenBank Accession Number ACC:CAA31343 (1988)</i>
	C17	<i>GenBank Accession Number ACC:X60933 (1991)</i>
	C18	<i>GenBank Accession Number ACC:X15059 (1989)</i>
	C19	<i>GenBank Accession Number ACC:X06220 (1986)</i>
	C20	<i>GenBank Accession Number ACC:Z18217 (1992)</i>
	C21	<i>GenBank Accession Number ACC:X63875 S41966 (1992)</i>
	C22	<i>GenBank Accession Number ACC:CAA40958 (1991)</i>
	C23	<i>GenBank Accession Number HSU19948 ACC:CAA31009 (1988)</i>
	C24	<i>GenBank Accession Number X68721 (1993)</i>
	C25	<i>GenBank Accession Number SPTREMBL-ACC:Q9Y3A6 (May, 1999)</i>
	C26	Gladson, C. L. (1999). "The Extracellular Matrix of Gliomas: Modulation of Cell Function." <i>J Neuropathol Exp Neurol</i> 58(10): 1029-40.
	C27	Hoshino, K., et al. (1999). "The Absence of Interleukin 1 Receptor-related T1/ST2 Does Not Affect T Helper Cell Type 2 Development and Its Effector Function." <i>J Exp Med</i> 190(10): 1541-7.
	C28	Jahkola, T., et al. (1998). "Expression of Tenascin-C in Intraductal Carcinoma of Human Breast: Relationship to Invasion." <i>Eur J Cancer</i> 34(11): 1687-92.
	C29	Jahkola, T., et al. (1998). "Tenascin-C expression in invasion border of early breast cancer: a predictor of local and distant recurrence." <i>Br J Cancer</i> 78(11): 1507-13.
	C30	Lee, Y. H., et al. (1996). "The Expression of and Insulin Binding to Cellular Thyroid Hormone Binding Protein, but not Insulin Degrading Enzyme, is Increased During 3T3-L1 Adipocytes Differentiation." <i>Biochem Biophys Res Commun</i> 222(3): 839-43.
	C31	Notterpek, L. M. (1994). "A Protein Involved in Central Nervous System Myelination: Localization in the Extracellular Matrix and Induction in Neuroblastoma Cells." <i>Dev Neurosci</i> 16(5-6): 267-78.
	C32	Otaki, J. M. et al., (1999). "Neurestin: Putative Transmembrane Molecule Implicated in Neuronal Development." <i>Dev Biol</i> 212(1): 165-81.
	C33	Phillips, G. R., et al. (1998). "Domains of tenascin involved in glioma migration." <i>J Cell Sci</i> 111(Pt 8): 1095-104.
	C34	Treasurywala, S. et al., (1998). "Migration Arrest in Glioma Cells is Dependent on the Integrin Subunit." <i>Glia</i> 24(2): 236-43.
	C35	Vollmer, G., et al. (1992). "Down-Regulation of Tenascin Expression by Antiprogestins during Terminal Differentiation of Rat Mammary Tumors." <i>Cancer Res</i> 52(17): 4642-8.
	C36	Wilson, K. E., et al. (1996). "Expression of the extracellular matrix protein tenascin in malignant and benign ovarian tumours." <i>Br J Cancer</i> 74(7): 999-1004.

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	C37	Yamauchi, K., et al. (1987). "Sequence of membrane-associated thyroid hormone binding protein from bovine liver: its identity with protein disulphide isomerase." <u>Biochem Biophys Res Commun</u> 146(3): 1485-92.
	C38	Yu, D., et al. (1998). "Overexpression of ErbB2 Blocks Taxol-induced Apoptosis by Upregulation of p21 <sup>Cip1</sup> , which Inhibits p34 <sup>Cdc2</sup> kinase." <u>Mol Cell</u> 2(5): 581-91.
	C39	GenBank Accession No. ACC::P71959 Hypothetical 9.9KD Protein CY441.31 - Mycobacterium Tuberculosis.

\* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. \_\_\_\_\_, filed \_\_\_\_\_, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.

Please type a plus sign (+) in this box



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

Approved for use through 9/30/00. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

PTO/SB (12-97)

<b>Modified Form 1449/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)	<b>Application Number</b>	09/584,411
	<b>Filing Date</b>	May 31, 2000
	<b>First Named Inventor</b>	Richard A. Shimkets
	<b>Group Art Unit</b>	1641
	<b>Examiner Name</b>	
	<b>Attorney Docket Number</b>	15966-552

10/15/01  
09/977418  
10/15/01

U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS						
Exam Initials	Cite No.	Foreign Patent Document Office Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No	

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	C40	Lai, et al., EMBL AF 151858 (1999).
	C41	Lai, et al., Genome Research 10(5):703-13 (2000).
	C42	Vijayasradhi, et al., J. Cell Biology 130(4):807-20 (1995).

\* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. \_\_\_\_\_, filed \_\_\_\_\_, and relied upon for an earlier filing date under 35 U.S.C. § 120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.